Base de dados : MEDLINE
Pesquisa : E02.095.465.425.400.330 [Categoria DeCS]
Referências encontradas : 16300 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1630 ir para página                         

  1 / 16300 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29420464
[Au] Autor:Vora NM; Orciari LA; Bertumen JB; Damon I; Ellison JA; Fowler VG; Franka R; Petersen BW; Satheshkumar PS; Schexnayder SM; Smith TG; Wallace RM; Weinstein S; Williams C; Yager P; Niezgoda M
[Ti] Título:Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin.
[So] Source:MMWR Morb Mortal Wkly Rep;67(5):161-165, 2018 Feb 09.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Rabies is an acute encephalitis that is nearly always fatal. It is caused by infection with viruses of the genus Lyssavirus, the most common of which is Rabies lyssavirus. The Council of State and Territorial Epidemiologists (CSTE) defines a confirmed human rabies case as an illness compatible with rabies that meets at least one of five different laboratory criteria.* Four of these criteria do not depend on the patient's rabies vaccination status; however, the remaining criterion, "identification of Lyssavirus-specific antibody (i.e. by indirect fluorescent antibody…test or complete [Rabies lyssavirus] neutralization at 1:5 dilution) in the serum," is only considered diagnostic in unvaccinated patients. Lyssavirus-specific antibodies include Rabies lyssavirus-specific binding immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies and Rabies lyssavirus neutralizing antibodies (RLNAs). This report describes six patients who were tested for rabies by CDC and who met CSTE criteria for confirmed human rabies because they had illnesses compatible with rabies, had not been vaccinated for rabies, and were found to have serum RLNAs (with complete Rabies lyssavirus neutralization at a serum dilution of 1:5). An additional four patients are described who were tested for rabies by CDC who were found to have serum RLNAs (with incomplete Rabies lyssavirus neutralization at a serum dilution of 1:5) despite having not been vaccinated for rabies. None of these 10 patients received a rabies diagnosis; rather, they were considered to have been passively immunized against rabies through recent receipt of intravenous immune globulin (IVIG). Serum RLNA test results should be interpreted with caution in patients who have not been vaccinated against rabies but who have recently received IVIG.
[Mh] Termos MeSH primário: Imunoglobulinas Intravenosas/administração & dosagem
Raiva/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Reações Falso-Positivas
Feminino
Seres Humanos
Imunização Passiva
Lyssavirus/isolamento & purificação
Masculino
Meia-Idade
Vacinas Antirrábicas/administração & dosagem
Vírus da Raiva/isolamento & purificação
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulins, Intravenous); 0 (Rabies Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6705a3


  2 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468884
[Au] Autor:Gardner CL; Sun C; Luke T; Raviprakash K; Wu H; Jiao JA; Sullivan E; Reed DS; Ryman KD; Klimstra WB
[Ad] Endereço:University of Pittsburgh Center for Vaccine Research, Pittsburgh, Pennsylvania, USA.
[Ti] Título:Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus.
[So] Source:J Virol;91(14), 2017 Jul 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus that causes low mortality but high morbidity rates in humans. In addition to natural outbreaks, there is the potential for exposure to VEEV via aerosolized virus particles. There are currently no FDA-licensed vaccines or antiviral therapies for VEEV. Passive immunotherapy is an approved method used to protect individuals against several pathogens and toxins. Human polyclonal antibodies (PAbs) are ideal, but this is dependent upon serum from convalescent human donors, which is in limited supply. Non-human-derived PAbs can have serious immunoreactivity complications, and when "humanized," these antibodies may exhibit reduced neutralization efficiency. To address these issues, transchromosomic (Tc) bovines have been created, which can produce potent neutralizing human antibodies in response to hyperimmunization. In these studies, we have immunized these bovines with different VEEV immunogens and evaluated the protective efficacy of purified preparations of the resultant human polyclonal antisera against low- and high-dose VEEV challenges. These studies demonstrate that prophylactic or therapeutic administration of the polyclonal antibody preparations (TcPAbs) can protect mice against lethal subcutaneous or aerosol challenge with VEEV. Furthermore, significant protection against unrelated coinfecting viral pathogens can be conferred by combining individual virus-specific TcPAb preparations. With the globalization and spread or potential aerosol release of emerging infectious diseases, it will be critical to develop platforms that are able to produce therapeutics in a short time frame. By using a transchromosomic (Tc) bovine platform, it is theoretically possible to produce antigen-specific highly neutralizing therapeutic polyclonal human antibody (TcPAb) preparations in 6 months or less. In this study, we demonstrate that Tc bovine-derived Venezuelan equine encephalitis virus (VEEV)-specific TcPAbs are highly effective against VEEV infection that mimics not only the natural route of infection but also infection via aerosol exposure. Additionally, we show that combinatorial TcPAb preparations can be used to treat coinfections with divergent pathogens, demonstrating that the Tc bovine platform could be beneficial in areas where multiple infectious diseases occur contemporaneously or in the case of multipathogen release.
[Mh] Termos MeSH primário: Animais Geneticamente Modificados
Anticorpos Antivirais/administração & dosagem
Vírus da Encefalite Equina Venezuelana/imunologia
Encefalomielite Equina Venezuelana/prevenção & controle
Encefalomielite Equina Venezuelana/terapia
Imunização Passiva
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/isolamento & purificação
Bovinos
Modelos Animais de Doenças
Seres Humanos
Camundongos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  3 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29176765
[Au] Autor:Giordano D; Draves KE; Young LB; Roe K; Bryan MA; Dresch C; Richner JM; Diamond MS; Gale M; Clark EA
[Ad] Endereço:Department of Immunology, University of Washington, Seattle, Washington, United States of America.
[Ti] Título:Protection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization.
[So] Source:PLoS Pathog;13(11):e1006743, 2017 Nov.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:B cell activating factor receptor (BAFFR)-/- mice have a profound reduction in mature B cells, but unlike µMT mice, they have normal numbers of newly formed, immature B cells. Using a West Nile virus (WNV) challenge model that requires antibodies (Abs) for protection, we found that unlike wild-type (WT) mice, BAFFR-/- mice were highly susceptible to WNV and succumbed to infection within 8 to 12 days after subcutaneous virus challenge. Although mature B cells were required to protect against lethal infection, infected BAFFR-/- mice had reduced WNV E-specific IgG responses and neutralizing Abs. Passive transfer of immune sera from previously infected WT mice rescued BAFFR-/- and fully B cell-deficient µMT mice, but unlike µMT mice that died around 30 days post-infection, BAFFR-/- mice survived, developed WNV-specific IgG Abs and overcame a second WNV challenge. Remarkably, protective immunity could be induced in mature B cell-deficient mice. Administration of a WNV E-anti-CD180 conjugate vaccine 30 days prior to WNV infection induced Ab responses that protected against lethal infection in BAFFR-/- mice but not in µMT mice. Thus, the immature B cells present in BAFFR-/- and not µMT mice contribute to protective antiviral immunity. A CD180-based vaccine may promote immunity in immunocompromised individuals.
[Mh] Termos MeSH primário: Anticorpos Antivirais/imunologia
Linfócitos B/imunologia
Febre do Nilo Ocidental/prevenção & controle
Vírus do Nilo Ocidental/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/imunologia
Receptor do Fator Ativador de Células B/deficiência
Receptor do Fator Ativador de Células B/genética
Feminino
Seres Humanos
Imunização Passiva
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Vacinação
Febre do Nilo Ocidental/imunologia
Febre do Nilo Ocidental/virologia
Vírus do Nilo Ocidental/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (B-Cell Activation Factor Receptor)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180210
[Lr] Data última revisão:
180210
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1006743


  4 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29323843
[Au] Autor:Borisevich IV; Chemikova NK; Markov VI; Krasnianskiy VP; Borisevich SV; Rozhdestvenskiy EV
[Ti] Título:An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever.
[So] Source:Vopr Virusol;62(1):25-9, 2017.
[Is] ISSN:0507-4088
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The aim of this work was to estimate the efficacy and safety of single intramuscular introduction of specific heterologous immunoglobulin as prophylactic drug against Ebola hemorrhagic fever. Materials and methods. The specific heterologous immunoglobulin was introduced as a special prophylactic drug to 28 patients in epidemic situations, after skin hurt with infectious materials or contact with infectious blood. Clinico-laboratory observation was performed in 24 subjects after single intramuscular introduction of heterologous immunoglobulin Ebola. The samples of blood serum were investigated for immunoglobulin Ebola and antibodies to horse gamma-globulin on the 30th and 60th days after prophylaxis. Results. None of the subjects of the study contracted Ebola fever. There were no anaphylactic reactions after special prophylaxis with specific heterologous immunoglobulin. Among the subjects with normal allergic state 31% responded with local reactions; 13%, with a general reaction (mild case of the serum disease). Almost no reaction was observed in patients with unfavorable allergic state subjected to desensitizing therapy; in the absence of desensitizing therapy, 50% of patients with unfavorable allergic state exhibited local reactions; 17%, mild cases of the serum disease; 33%, moderate cases of the serum disease. In summary, if the tactics of immunoglobulin application was right, the quantity of local allergic reactions was 28%; of wide spread reactions, 6%. Weak serum disease was observed in 11% of the subjects. The prognostic period of resistance to Ebola fever was less than 30 days. Conclusion. The prophylactic use of specific immunoglobulin from horse blood serum against hemorrhagic Ebola fever is effective and relatively safe in patients subjected to desensitizing therapy.
[Mh] Termos MeSH primário: Anticorpos Antivirais/administração & dosagem
Ebolavirus/imunologia
Doença pelo Vírus Ebola/prevenção & controle
Imunoglobulina G/administração & dosagem
Profilaxia Pré-Exposição/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Animais
Anticorpos Antivirais/efeitos adversos
Anticorpos Antivirais/sangue
Criança
Busca de Comunicante
Dessensibilização Imunológica
Ebolavirus/patogenicidade
Feminino
Doença pelo Vírus Ebola/imunologia
Doença pelo Vírus Ebola/transmissão
Doença pelo Vírus Ebola/virologia
Cavalos/sangue
Cavalos/imunologia
Seres Humanos
Hipersensibilidade/imunologia
Hipersensibilidade/fisiopatologia
Imunização Passiva
Imunoglobulina G/efeitos adversos
Imunoglobulina G/sangue
Injeções Intramusculares
Masculino
Meia-Idade
Ferimentos Penetrantes Produzidos por Agulha/imunologia
Segurança do Paciente
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE


  5 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463876
[Au] Autor:Anderson DJ; Politch JA; Zeitlin L; Hiatt A; Kadasia K; Mayer KH; Ruprecht RM; Villinger F; Whaley KJ
[Ad] Endereço:aDepartments of Obstetrics and Gynecology Boston University School of Medicine, Boston, Massachusetts bMapp Biopharmaceutical, San Diego California cDepartment of Molecular Medicine, Boston University School of Medicine dFenway Health, Harvard Medical School, Boston, Massachusetts eTexas Biomedical Institute, Southwest National Primate Research Center, San Antonio, Texas fNew Iberia Primate Center, New Iberia, Louisiana, USA.
[Ti] Título:Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.
[So] Source:AIDS;31(11):1505-1517, 2017 Jul 17.
[Is] ISSN:1473-5571
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:: Passive immunization, the transfer of antibodies to a nonimmune individual to provide immunological protection, has been used for over 100 years to prevent and treat human infectious diseases. The introduction of techniques to produce human mAbs has revolutionized the field, and a large number of human mAbs have been licensed for the treatment of cancer, autoimmune and inflammatory diseases. With the recent discovery and production of highly potent broadly neutralizing and other multifunctional antibodies to HIV, mAbs are now being considered for HIV therapy and prophylaxis. In this review, we briefly present recent advances in the anti-HIV mAb field and outline strategies for the selection, engineering and production of human mAbs, including the modification of their structure for optimized stability and function. We also describe results from nonhuman primate studies and phase 1 clinical trials that have tested the safety, tolerability, pharmacokinetics, and efficacy of mAb-based HIV prevention strategies, and discuss the future of parenteral and topical mAb administration for the prevention of HIV transmission.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Monoclonais/farmacologia
Anticorpos Anti-HIV/efeitos dos fármacos
Anticorpos Anti-HIV/imunologia
Infecções por HIV/prevenção & controle
Imunização Passiva
Profilaxia Pré-Exposição/métodos
Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle
[Mh] Termos MeSH secundário: Administração Tópica
Animais
Anticorpos Monoclonais/administração & dosagem
Feminino
Infecções por HIV/transmissão
HIV-1/efeitos dos fármacos
Seres Humanos
Imunização Passiva/métodos
Reto/virologia
Síndrome de Imunodeficiência Adquirida dos Símios/transmissão
Vírus da Imunodeficiência Símia/efeitos dos fármacos
Resultado do Tratamento
Vagina/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (HIV Antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1097/QAD.0000000000001521


  6 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28916870
[Au] Autor:Yuan X; Lin H; Li B; He K; Fan H
[Ad] Endereço:College of Veterinary Medicine, Nanjing Agricultural University, No. 1 Weigang, Nanjing, 210095, China.
[Ti] Título:Efficacy and immunogenicity of recombinant swinepox virus expressing the truncated S protein of a novel isolate of porcine epidemic diarrhea virus.
[So] Source:Arch Virol;162(12):3779-3789, 2017 Dec.
[Is] ISSN:1432-8798
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:Porcine epidemic diarrhea virus (PEDV) causes significant loss to the swine industry. The emergence of novel PEDV strains in recent years has decreased the effectiveness of PEDV vaccines. We have developed a live recombinant vaccine, a swinepox virus vector that expresses a truncated S protein (rSPV-St) from a recent PEDV strain, SQ2014, and evaluated its immunogenicity and effectiveness in a swine model. Vaccination of swine with rSPV-St elicited a robust antibody response specific for the homologous PEDV SQ2014. Serum IgA titers in rSPV-St-vaccinated animals were significantly higher than in those immunized with inactivated vaccines. The effectiveness of antibodies induced by the rSPV-St vaccine in protection against PEDV was tested in a passive-transfer model in which piglets were challenged with the homologous virus SQ2014 and the heterologous strain CV777. When challenged with the homologous virus, sera from rSPV-St vaccination provided complete protection. However, sera from rSPV-St vaccination did not provide any protection against the heterologous virus challenge. Amino acid sequence differences in the S proteins of the two viruses were identified within neutralizing epitopes, which might have contributed to the divergent clinical results. Our data suggest that rSPV-St is potentially an effective vaccine against infection with emerging PEDV strains.
[Mh] Termos MeSH primário: Infecções por Coronavirus/veterinária
Portadores de Fármacos
Vírus da Diarreia Epidêmica Suína/imunologia
Glicoproteína da Espícula de Coronavírus/imunologia
Suipoxvirus/genética
Doenças dos Suínos/prevenção & controle
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/sangue
Infecções por Coronavirus/prevenção & controle
Proteção Cruzada
Imunização Passiva
Imunoglobulina A/sangue
Vírus da Diarreia Epidêmica Suína/genética
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Glicoproteína da Espícula de Coronavírus/genética
Suínos
Resultado do Tratamento
Vacinas Atenuadas/administração & dosagem
Vacinas Atenuadas/genética
Vacinas Atenuadas/imunologia
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Vacinas Virais/administração & dosagem
Vacinas Virais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Drug Carriers); 0 (Immunoglobulin A); 0 (Recombinant Proteins); 0 (Spike Glycoprotein, Coronavirus); 0 (Vaccines, Attenuated); 0 (Vaccines, Synthetic); 0 (Viral Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170917
[St] Status:MEDLINE
[do] DOI:10.1007/s00705-017-3548-1


  7 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28768869
[Au] Autor:Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
[Ad] Endereço:Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, USA.
[Ti] Título:Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
[So] Source:J Virol;91(20), 2017 Oct 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:HIV broadly neutralizing antibodies (bnAbs) have been shown to occasionally display unusual virus neutralization profiles with nonsigmoidal slopes and plateaus at <100% neutralization against a variety of viruses. The significance of incomplete neutralization for the ability of bnAbs to mediate protective effects vo, however, is undetermined. In the current study, we selected two bnAbs, PGT121 and 3BNC117, as they incompletely neutralize the clade C simian-human immunodeficiency virus (SHIV) stock (SHIV-327c) at 85% and 70%, respectively, and performed a protection study in rhesus macaques. The animals were intravenously (i.v.) administered PGT121 or 3BNC117 at 10 and 2 mg/kg of body weight before being rectally challenged with a single high dose of SHIV-327c. PGT121 protected 6 out of 7 monkeys, while 6 out of 7 3BNC117-pretreated animals became infected, although with significantly delayed plasma viremia compared to the control animals. These data suggest that complete neutralization is not imperative for bnAbs to prevent infection but that with increasing levels of incomplete neutralization the sterilizing activity diminishes. Multiple antibodies have been identified that potently neutralize a broad range of circulating HIV strains. However, not every virus-antibody combination results in complete neutralization of the input virus, suggesting that a fraction of virus particles are resistant to antibody neutralization despite high antibody concentrations. This observation of "incomplete neutralization" is associated with nonsigmoidal neutralization curves plateauing below 100% neutralization, but the significance of the phenomenon for the ability of neutralizing antibodies to mediate protective effects is undetermined. In this study, we show that the broadly neutralizing antibody PGT121, which neutralized only up to 85% of the SHIV-327c challenge stock , protected 6 out of 7 rhesus macaques against infection while the antibody 3BNC117, which neutralized up to 70% of SHIV-327c , did not prevent, though it significantly delayed, establishment of infection, suggesting that with increasing levels of incomplete neutralization the ability of a bnAb to mediate sterilizing protection diminishes.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Neutralizantes/imunologia
Anticorpos Anti-HIV/imunologia
Infecções por HIV/prevenção & controle
HIV-1/imunologia
Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle
Vírus da Imunodeficiência Símia/imunologia
[Mh] Termos MeSH secundário: Administração Intravenosa
Animais
Anticorpos Monoclonais/administração & dosagem
Anticorpos Neutralizantes/administração & dosagem
Anticorpos Anti-HIV/administração & dosagem
Infecções por HIV/virologia
Seres Humanos
Imunização Passiva
Macaca mulatta
Testes de Neutralização
Síndrome de Imunodeficiência Adquirida dos Símios/sangue
Síndrome de Imunodeficiência Adquirida dos Símios/virologia
Vírus da Imunodeficiência Símia/fisiologia
Viremia/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (HIV Antibodies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE


  8 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28708268
[Au] Autor:Jolles S; Sánchez-Ramón S; Quinti I; Soler-Palacín P; Agostini C; Florkin B; Couderc LJ; Brodszki N; Jones A; Longhurst H; Warnatz K; Haerynck F; Matucci A; de Vries E
[Ad] Endereço:Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
[Ti] Título:Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group.
[So] Source:Clin Exp Immunol;190(2):226-234, 2017 Nov.
[Is] ISSN:1365-2249
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Many patients with primary immunodeficiency (PID) who have antibody deficiency develop progressive lung disease due to underlying subclinical infection and inflammation. To understand how these patients are monitored we conducted a retrospective survey based on patient records of 13 PID centres across Europe, regarding the care of 1061 adult and 178 paediatric patients with PID on immunoglobulin (Ig) G replacement. The most common diagnosis was common variable immunodeficiency in adults (75%) and hypogammaglobulinaemia in children (39%). The frequency of clinic visits varied both within and between centres: every 1-12 months for adult patients and every 3-6 months for paediatric patients. Patients diagnosed with lung diseases were more likely to receive pharmaceutical therapies and received a wider range of therapies than patients without lung disease. Variation existed between centres in the frequency with which some clinical and laboratory monitoring tests are performed, including exercise tests, laboratory testing for IgG subclass levels and specific antibodies, and lung function tests such as spirometry. Some tests were carried out more frequently in adults than in children, probably due to difficulties conducting these tests in younger children. The percentage of patients seen regularly by a chest physician, or who had microbiology tests performed following chest and sinus exacerbations, also varied widely between centres. Our survey revealed a great deal of variation across Europe in how frequently patients with PID visit the clinic and how frequently some monitoring tests are carried out. These results highlight the urgent need for consensus guidelines on how to monitor lung complications in PID patients.
[Mh] Termos MeSH primário: Síndromes de Imunodeficiência/fisiopatologia
Pneumopatias/complicações
Sistema Respiratório/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Agamaglobulinemia/fisiopatologia
Assistência Ambulatorial
Infecções Assintomáticas/epidemiologia
Criança
Imunodeficiência de Variável Comum/fisiopatologia
Europa (Continente)
Feminino
Seres Humanos
Imunização Passiva
Imunoglobulina G/uso terapêutico
Imunoglobulinas/uso terapêutico
Síndromes de Imunodeficiência/complicações
Síndromes de Imunodeficiência/imunologia
Síndromes de Imunodeficiência/terapia
Pneumopatias/diagnóstico
Pneumopatias/imunologia
Pneumopatias/prevenção & controle
Masculino
Registros Médicos
Guias de Prática Clínica como Assunto
Estudos Retrospectivos
Espirometria
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G); 0 (Immunoglobulins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.1111/cei.13012


  9 / 16300 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28645240
[Au] Autor:Ahmad M; Ahmed OM; Schnepp B; Johnson PR
[Ad] Endereço:College of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania 19104; email: mahama@sas.upenn.edu.
[Ti] Título:Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
[So] Source:Annu Rev Virol;4(1):491-510, 2017 Sep 29.
[Is] ISSN:2327-0578
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This review discusses recent progress made in developing a vaccine and novel treatments for human immunodeficiency virus (HIV). It highlights the shortcomings of the RV144 vaccination trial [ALVAC-HIV (vCP1521) and AIDSVAX B/E] and the current standard of care and proposes that engineered expression of broadly neutralizing antibodies (bNAbs) against HIV-1 could overcome these shortcomings. Current developments in three major lines of research on HIV prevention and treatment using bNAbs are reviewed: firstly, the use of sequential immunogens to activate B cells to express bNAbs; secondly, the delivery of novel and extremely potent bNAbs through passive administration; and finally, the use of gene transfer using adeno-associated viral vectors to deliver bNAbs.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/uso terapêutico
Anticorpos Anti-HIV/biossíntese
Infecções por HIV/prevenção & controle
Infecções por HIV/terapia
HIV-1/imunologia
[Mh] Termos MeSH secundário: Vacinas contra a AIDS/imunologia
Vacinas contra a AIDS/uso terapêutico
Animais
Anticorpos Neutralizantes/biossíntese
Anticorpos Neutralizantes/genética
Linfócitos B/imunologia
Ensaios Clínicos como Assunto
Engenharia Genética
Terapia Genética
Vetores Genéticos
Anticorpos Anti-HIV/genética
Anticorpos Anti-HIV/uso terapêutico
Infecções por HIV/imunologia
Infecções por HIV/virologia
Seres Humanos
Imunização Passiva
Camundongos
Produtos do Gene env do Vírus da Imunodeficiência Humana
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (AIDS Vaccines); 0 (AIDSVAX); 0 (AIDSVAX B-E); 0 (Antibodies, Neutralizing); 0 (HIV Antibodies); 0 (env Gene Products, Human Immunodeficiency Virus)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170625
[St] Status:MEDLINE
[do] DOI:10.1146/annurev-virology-101416-041929


  10 / 16300 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28633319
[Au] Autor:Zhang BZ; Cai J; Yu B; Xiong L; Lin Q; Yang XY; Xu C; Zheng S; Kao RY; Sze K; Yuen KY; Huang JD
[Ad] Endereço:School of Biomedical Sciences.
[Ti] Título:Immunotherapy Targeting Adenosine Synthase A Decreases Severity of Staphylococcus aureus Infection in Mouse Model.
[So] Source:J Infect Dis;216(2):245-253, 2017 Jul 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Staphylococcusaureus is a severe pathogen found in the community and in hospitals. Most notably, methicillin-resistant S. aureus (MRSA) is resistant to almost all antibiotics, which is a growing public health concern. The emergence of drug-resistant strains has prompted the search for alternative treatments such as immunotherapeutic approaches. Previous research showed that S. aureus exploit the immunomodulatory attributes of adenosine to escape host immunity. In this study, we investigated adenosine synthase A (AdsA), an S. aureus cell wall-anchored enzyme as possible targets for immunotherapy. Mice vaccinated with aluminum hydroxide-formulated recombinant AdsA (rAdsA) induced high-titer anti-AdsA antibodies, thereby providing consistent protection in 3 mouse infection models when challenged with 2 S. aureus strains. The importance of anti-AdsA antibody in protection was demonstrated by passive transfer experiments. Moreover, AdsA-specific antisera promote killing S. aureus by immune cells. Altogether, our data demonstrate that the AdsA is a promising target for vaccines and therapeutics development to alleviate severe S. aureus diseases.
[Mh] Termos MeSH primário: Anticorpos Antibacterianos/farmacologia
Proteínas de Bactérias/imunologia
Imunização Passiva
Ligases/imunologia
Infecções Cutâneas Estafilocócicas/terapia
[Mh] Termos MeSH secundário: Adenosina/biossíntese
Animais
Antibacterianos/uso terapêutico
Modelos Animais de Doenças
Feminino
Imunoterapia
Camundongos
Camundongos Endogâmicos BALB C
Coelhos
Staphylococcus aureus/enzimologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antibodies, Bacterial); 0 (Bacterial Proteins); EC 6.- (Ligases); K72T3FS567 (Adenosine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix290



página 1 de 1630 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde